1. Italy Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Amplifon SpA

Amplifon SpA

12.83
EUR
+0.15
(+1.18%)
0.44EPS
21.56P/E
2.50BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.81
4.1
4.74
5.17
5.78
6.2
7.81
6.72
8.66
9.45
10.01
10.69
10.89
10.47
Basic EPS, GAAP
0.06
0.21
0.21
0.29
0.46
0.46
0.49
0.45
0.7
0.8
0.69
0.65
0.42
0.44
Free Cash Flow per Basic Share
0.25
0.34
0.36
0.37
0.44
0.47
1.03
1.48
1.55
1.53
1.2
1.35
1.35
1.46
Dividend per Share
0.04
0.04
0.04
0.04
0.07
0.11
0.14
- -
0.22
0.26
0.29
0.29
0.3
- -
Book Value per Share
1.75
2.04
2.28
2.54
2.69
2.7
3.12
3.56
4.11
4.62
4.88
5.1
4.54
5.7
Tangible Book Value per Share
-1.11
-1.05
-0.98
-1.09
-1.35
-4.2
-3.98
-3.75
-5.2
-5.06
-4.94
-5.43
-5.95
-3.1
Basic Weighted Avg Shares
217
217
218
219
219
220
222
224
225
224
226
225
220
232
Sales/Revenue/Turnover
827
891
1,034
1,133
1,266
1,362
1,732
1,503
1,948
2,119
2,260
2,409
2,396
2,427
Operating Margin (%)
8.53
10.24
11.07
11.86
11.91
11.57
10.4
11.1
12.52
12.61
11.09
10.51
8.55
10.74
Depreciation Expense
48
47
52
54
63
72
193
202
222
240
268
303
315
308
Net Income, GAAP
13
46
47
64
101
100
109
101
158
179
155
145
91
101
Effective Tax Rate (%)
64.93
30.22
46.98
40.6
22.91
27.54
27.72
27.81
26.76
26.65
26.09
26.02
30.53
34.31
Profit Margin (%)
1.55
5.22
4.53
5.61
7.94
7.37
6.27
6.72
8.1
8.42
6.86
6.03
3.81
4.17
Working Capital
109
139
128
102
-234
-75
-236
170
-240
-463
-558
-445
-493
-425
LT Debt
418
439
394
399
124
873
1,094
1,407
1,364
1,168
1,094
1,345
1,351
927
Total Equity
381
443
500
558
588
596
696
802
927
1,040
1,102
1,150
999
1,514
Return on Invested Capital (%)
2.9
7.43
6.55
8.05
11.66
8.8
7.16
5.28
7.24
7.9
7.25
6.79
4.72
8.12
Return on Capital (%)
2.7
7.21
6.63
7.96
11.76
8.84
7.25
5.53
7.27
7.91
7.29
6.84
4.66
4.52
Return on Common Equity (%)
3.17
11.3
9.94
12.04
17.55
16.97
16.85
13.5
18.28
18.18
14.5
12.92
8.5
7.63

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
469
819
849
LT Borrowings
987
610
568
LT Finance Leases
364
360
359
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
220
220
266
Market Capitalization
3,016
2,075
2,501

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
763
763
1,164
Cash, Cash Equivalents & STI
309
310
713
Accounts Receivable, Net
222
232
229
Inventories
82
88
80
Total Current Liabilities
1,256
1,591
1,589
Payables & Accruals
- -
- -
- -
ST Debt
469
819
849
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.52%
4.99%
-13.19%
Free Cash Flow
18.87%
-1.51%
-2.75%
Net Income, GAAP
10.78%
2.56%
-37.17%
Sales/Revenue/Turnover
9.39%
10.21%
-0.56%
Total Cash Common Dividend
- -
- -
-0.44%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
573
604
573
659
2,409
2025
588
593
- -
649
2,396
2026
580
606
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.23
0.07
0.18
0.65
2025
0.15
0.16
- -
0.08
0.42
2026
0.05
0.15
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.29
2025
- -
- -
- -
- -
0.3
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Enrico Vita
Full Time Employees
15,078
Sector
Distribution services
Industry
Medical distributors
Address
Via Ripamonti 133 Milan MI Italy 20141
IPO Date
Jun 27, 2001
Website
amplifon.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Amplifon S.p.A. is a global leader in hearing care retail, headquartered in Milan, Italy, and founded in 1950. The company specializes in the distribution, customization, and fitting of hearing solutions designed to help individuals rediscover the emotions of sound. Its core product portfolio includes a wide range of hearing aids and auditory prostheses under brands such as Amplifon, Miracle-Ear, Beter Horen, and Sonus, complemented by advanced hearing aid technologies like Ampli-Easy, Ampli-Mini, Ampli-Connect, and Ampli-Energy. These products feature innovative functions such as Bluetooth connectivity, noise reduction, and rechargeable batteries, aimed at enhancing user experience. Amplifon also provides comprehensive services including hearing diagnosis, fitting, maintenance, and personalized customer care. The company operates through an extensive global network of approximately 10,000 points of sale including owned stores, franchise outlets, and shop-in-shops, covering Europe, the Middle East, Africa (EMEA), the Americas, and Asia-Pacific regions. Its geographic presence spans major markets such as Italy, France, Germany, the United States, Canada, Australia, China, and several Latin American countries, reflecting a diversified and robust international footprint. Recent strategic initiatives include the acceleration of the "Fit4Growth" program aimed at improving operational efficiency and profitability by restructuring its retail network, including the selective closure of around 100 underperforming clinics as of late 2025. Amplifon has pursued growth through acquisitions primarily in France, Germany, Poland, the United States, Canada, and China, reinforcing its market position in these key territories. In 2024, the company reported revenue growth supported by these acquisitions and organic expansion, with a focus on maximizing performance in the US market through its Miracle-Ear and Amplifon Hearing Healthcare businesses. Amplifon also emphasizes technological innovation and digital transformation to strengthen its competitive edge and enhance customer engagement. Amplifon is positioned within the hearing care and medical equipment industry, targeting hearing-impaired individuals requiring customized auditory solutions and services. The company’s advanced product offerings, combined with a global retail presence and ongoing strategic initiatives, affirm its leadership role and commitment to sustained growth in the hearing care market. This comprehensive profile reflects Amplifon's main products and services alongside its latest significant operational and strategic changes.